Analysis shows therapy use and lower costs in patients with acute myeloid leukemia, suggesting a need for more second-line treatment.
A growing number of patients enrolled in Medicare Fee-For-Service with AML use first-line venetoclax. Older patients and those with comorbidities are less likely to initiate second-line therapy. Costs were lower and length of stay was shorter than described in previous research.
No takes yet. Share an insight, caveat, or question.
D'Amico et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: